

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Bogue Zachary</u> (Last) (First) (Middle) 270 UNIVERSITY AVENUE (Street) PALO CA 94301 ALTO (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 04/15/2021	3. Issuer Name and Ticker or Trading Symbol <u>RECURSION PHARMACEUTICALS, INC. [RXXR]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series A Preferred Stock	(1)	(1)	Common Stock ⁽¹⁾	3,771,996	0.00	I	See footnote ⁽²⁾
Series B Preferred Stock	(1)	(1)	Common Stock ⁽¹⁾	1,073,595	0.00	I	See footnote ⁽²⁾
Series B Preferred Stock	(1)	(1)	Common Stock ⁽¹⁾	3,220,788	0.00	I	See footnote ⁽³⁾
Series C Preferred Stock	(1)	(1)	Common Stock ⁽¹⁾	1,095,529	0.00	I	See footnote ⁽²⁾
Series C Preferred Stock	(1)	(1)	Common Stock ⁽¹⁾	730,353	0.00	I	See footnote ⁽³⁾
Series D Preferred Stock	(1)	(1)	Common Stock ⁽¹⁾	3,726,963	0.00	I	See footnote ⁽⁴⁾

Explanation of Responses:

1. Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date.

2. Represents shares held of record by Data Collective IV, L.P. (DCVC IV). Data Collective IV GP, LLC (DCVC IV GP) is the general partner of DCVC IV and has sole voting and dispositive power with regard to the shares held by DCVC IV. Matthew Ocko and Zachary Bogue are the managing members of DCVC IV GP and share voting and dispositive power with respect to the shares held by DCVC IV. The Reporting Person disclaims the existence of a group and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such persons indirect pecuniary interest therein, if any.

3. Represents shares held of record by DCVC Opportunity Fund II, L.P. (DCVC Opp Fund II). DCVC Opportunity Fund II GP, LLC (DCVC Opp Fund II GP) is the general partner of DCVC Opp Fund II and has sole voting and dispositive power with regard to the shares held by DCVC Opp Fund II. Matthew Ocko and Zachary Bogue are the managing members of DCVC Opp Fund II GP and share voting and dispositive power with respect to the shares held by DCVC Opp Fund II. The Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such persons indirect pecuniary interest therein, if any.

4. Represents shares held of record by DCVC V, L.P. (DCVC V). DCVC V GP, LLC (DCVC V GP) is the general partner of DCVC V and has sole voting and dispositive power with regard to the shares held by DCVC V. Matthew Ocko and Zachary Bogue are the managing members of DCVC V GP and share voting and dispositive power with respect to the shares held by DCVC V. The Reporting Person disclaims the existence of a group and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such persons indirect pecuniary interest therein, if any.

Remarks:

/s/ Zachary Bogue

04/15/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.